These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Response of patients with bleeding disorder to DDAVP administration. Chuansumrit A, Hathirat P, Pintadit P, Isarangkura P. Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():174-9. PubMed ID: 7886567 [Abstract] [Full Text] [Related]
25. Laboratory diagnosis and molecular classification of von Willebrand disease. Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352 [Abstract] [Full Text] [Related]
26. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease. Mohri H, Hashimoto Y, Yamazaki E, Kanamori H, Okubo T. Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359 [Abstract] [Full Text] [Related]
29. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Sánchez-Luceros A, Meschengieser SS, Woods AI, Chuit R, Turdó K, Blanco A, Lazzari MA. Thromb Haemost; 2010 Nov; 104(5):984-9. PubMed ID: 20886181 [Abstract] [Full Text] [Related]
30. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1. Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z. Acta Haematol; 2009 Nov; 121(2-3):119-27. PubMed ID: 19506358 [Abstract] [Full Text] [Related]
31. [DDAVP administration in a case of congenital combined factor V and factor VIII deficiency]. Takai Y, Hayashi H, Ishimaru F, Fujita T, Tsurumi N, Tsuda T, Kimura I. Rinsho Ketsueki; 1989 Nov; 30(11):2035-40. PubMed ID: 2607619 [Abstract] [Full Text] [Related]
33. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Mannucci PM. Prog Hemost Thromb; 1986 Nov; 8():19-45. PubMed ID: 3104987 [Abstract] [Full Text] [Related]
34. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies. Ghirardini A, Mariani G, Iacopino G, Tirindelli MC, Solinas S, Moretti T. Thromb Haemost; 1987 Oct 28; 58(3):896-8. PubMed ID: 3124287 [Abstract] [Full Text] [Related]
35. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders. Mörsdorf S, Köhler M, Leipnitz G, Wenzel E. Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Oct 28; 115(4):503-7. PubMed ID: 2465962 [Abstract] [Full Text] [Related]
37. DDAVP (desmopressin) in the dental management of patients with mild or moderate hemophilia and von Willebrand's disease. Vierrou AM, de la Fuente B, Poole AE, Hoyer LW. Pediatr Dent; 1985 Dec 28; 7(4):297-301. PubMed ID: 2938080 [No Abstract] [Full Text] [Related]
38. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. Guddati AK, Rosovsky RP, Van Cott EM, Kuter DJ. Int J Lab Hematol; 2019 Jun 28; 41(3):325-330. PubMed ID: 30735311 [Abstract] [Full Text] [Related]
40. [DDAVP: alternative to replacement treatment in mild haemophilia A and von Willebrand-Jürgens syndrome (author's transl)]. Theiss W, Sauer E. Dtsch Med Wochenschr; 1977 Dec 02; 102(48):1769-72. PubMed ID: 303563 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]